Agenus to Host Stakeholder Webcast on Immuno-Oncology Advancements on August 27, 2025

Agenus will host a virtual Stakeholder Briefing on August 27 to discuss recent immuno-oncology advancements, including BOT/BAL clinical data and partnership updates. The event will cover CRC studies, BATTMAN Phase 3 study, and MiNK Therapeutics, with a live Q&A session featuring company leaders and experts. The briefing will provide insights into Agenus' work in cancer immunotherapy, leveraging Botensilimab and Balstilimab.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event aims to provide insights into recent advancements in immuno-oncology, including clinical data from the BOT/BAL program and updates on partnerships. The briefing will cover various topics, including colorectal cancer (CRC) studies, the Phase 3 BATTMAN study, and collaborations with MiNK Therapeutics, with a live Q&A session featuring company leaders and experts.

Key highlights of the briefing include a strategic and financial overview, updates on the Zydus partnership, and patient needs fueling interest in CRC studies. The agenda will also cover recent clinical data from the botensilimab (BOT) and balstilimab (BAL) program, as well as an overview of the Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will feature a spotlight on MiNK Therapeutics and upcoming milestones across Agenus' portfolio.

Speakers at the event will include Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Richard M. Goldberg, MD, Chief Development Officer; Jennifer Buell, PhD, CEO of MiNK Therapeutics; Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University; and Chris O'Callaghan, DVM, MSc, PhD, Senior Investigator at Canadian Cancer Trials Group (CCTG).

The virtual briefing will be accessible via the link [https://riverside.fm/studio/agenus-presentation](https://riverside.fm/studio/agenus-presentation), with no pre-registration required. The event is open to all stakeholders and investors interested in Agenus' work in cancer immunotherapy and its portfolio of immunological agents.

References:
[1] https://www.businesswire.com/news/home/20250826512064/en/Update-Agenus-Aug-27-Stakeholder-WebcastTransformative-IO-Updates-BOTBAL-Data-BATTMAN-Preview-Zydus-Partnership-Momentum-and-MiNK-Spotlight
[2] https://www.biospace.com/press-releases/agenus-to-unveil-bot-bal-strategic-advancements-key-milestones-and-future-outlook-in-virtual-stakeholder-briefing-on-august-27-2025